Does inhibition of EGFR/STAT3/CEBPD axis reverse cisplatin cross-resistance with paclitaxel in urothelial carcinoma of urinary bladder?
Our results revealed the risk of CEBPD activation in CDDP-resistant UCUB cells and suggested a therapeutic strategy for patients with UCUB or UCUB resisted to CDDP and PTX by combination with either gefitinib or S3I-201.
We conclude that the downregulation of DKK-1 is responsible for the high proliferation ability of LM-MCF-7 breast cancer cells via losing control of Wnt/beta-catenin signaling pathway, in which c-Myc, cyclinD1 and Survivin serve as essential downstream effectors. Our finding provides a new insight into the mechanism of breast cancer cell proliferation.